Barclays Capital Begins Covering Insulet Corporation (NDAQ:PODD) Stock. “Shares to Hit $65.00”

September 17, 2017 - By test

 Barclays Capital Begins Covering Insulet Corporation (NDAQ:PODD) Stock. “Shares to Hit $65.00”

Investors sentiment decreased to 0.87 in Q4 2016. Its down 0.25, from 1.12 in 2016Q3. It worsened, as 26 investors sold Insulet Corporation shares while 58 reduced holdings. 21 funds opened positions while 52 raised stakes. 60.26 million shares or 0.42% more from 60.00 million shares in 2016Q3 were reported.

Engineers Gate Manager Lp holds 0.07% or 18,088 shares. Peak6 Invests L P, a Illinois-based fund reported 3,730 shares. Frontier Capital Limited Company invested 0.46% in Insulet Corporation (NASDAQ:PODD). Janus Capital Management Limited Liability Corporation owns 0.02% invested in Insulet Corporation (NASDAQ:PODD) for 577,139 shares. X Mgmt Limited Liability Company invested in 0% or 134 shares. Slate Path Cap Limited Partnership reported 2.85 million shares stake. Sei Investments owns 12 shares for 0% of their portfolio. Gp One Trading Ltd Partnership holds 0% or 6,126 shares in its portfolio. Gilder Gagnon Howe Ltd Llc holds 0.01% or 14,970 shares in its portfolio. Trexquant Lp owns 9,563 shares. 32,665 are held by Pioneer Invest Mgmt. Wells Fargo And Company Mn accumulated 46,712 shares or 0% of the stock. Bnp Paribas Inv Prtnrs stated it has 0.17% in Insulet Corporation (NASDAQ:PODD). Essex Management Ltd Limited Liability Company has 66,936 shares. Brown Advisory has invested 0% of its portfolio in Insulet Corporation (NASDAQ:PODD).

Since May 1, 2017, it had 3 buys, and 1 sale for $251,188 activity. On Monday, May 1 the insider Lemoine David A sold $66,142. On Thursday, May 11 the insider Hopfield Jessica bought $99,783. On Tuesday, May 16 Spears Michael P bought $101,470 worth of Insulet Corporation (NASDAQ:PODD) or 2,500 shares. The insider Thomas Bradley A bought $116,077.

Why Has Barclays Capital Given Insulet Corporation (NDAQ:PODD) a $65.00 Price Target

In an analyst report issued to clients today, Barclays Capital analysts began Insulet Corporation (NDAQ:PODD) coverage with “Overweight” rating, and a $65.00 price target.

Investors sentiment decreased to 0.87 in Q4 2016. Its down 0.25, from 1.12 in 2016Q3. It worsened, as 26 investors sold Insulet Corporation shares while 58 reduced holdings. 21 funds opened positions while 52 raised stakes. 60.26 million shares or 0.42% more from 60.00 million shares in 2016Q3 were reported.

Engineers Gate Manager Lp holds 0.07% or 18,088 shares. Peak6 Invests L P, a Illinois-based fund reported 3,730 shares. Frontier Capital Limited Company invested 0.46% in Insulet Corporation (NASDAQ:PODD). Janus Capital Management Limited Liability Corporation owns 0.02% invested in Insulet Corporation (NASDAQ:PODD) for 577,139 shares. X Mgmt Limited Liability Company invested in 0% or 134 shares. Slate Path Cap Limited Partnership reported 2.85 million shares stake. Sei Investments owns 12 shares for 0% of their portfolio. Gp One Trading Ltd Partnership holds 0% or 6,126 shares in its portfolio. Gilder Gagnon Howe Ltd Llc holds 0.01% or 14,970 shares in its portfolio. Trexquant Lp owns 9,563 shares. 32,665 are held by Pioneer Invest Mgmt. Wells Fargo And Company Mn accumulated 46,712 shares or 0% of the stock. Bnp Paribas Inv Prtnrs stated it has 0.17% in Insulet Corporation (NASDAQ:PODD). Essex Management Ltd Limited Liability Company has 66,936 shares. Brown Advisory has invested 0% of its portfolio in Insulet Corporation (NASDAQ:PODD).

Since May 1, 2017, it had 3 buys, and 1 sale for $251,188 activity. On Monday, May 1 the insider Lemoine David A sold $66,142. On Thursday, May 11 the insider Hopfield Jessica bought $99,783. On Tuesday, May 16 Spears Michael P bought $101,470 worth of Insulet Corporation (NASDAQ:PODD) or 2,500 shares. The insider Thomas Bradley A bought $116,077.

Insulet Corporation (NASDAQ:PODD) Ratings Coverage

Among 4 analysts covering Insulet Corporation (NDAQ:PODD), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Insulet Corporation has $48 highest and $42 lowest target. $45.67’s average target is -23.19% below currents $59.46 stock price. Insulet Corporation had 5 analyst reports since May 11, 2017 according to SRatingsIntel. The firm earned “Hold” rating on Monday, May 29 by Canaccord Genuity. The stock of Insulet Corporation (NASDAQ:PODD) has “Buy” rating given on Friday, June 16 by Jefferies. The rating was reinitiated by William Blair on Thursday, May 25 with “Outperform”. As per Thursday, May 11, the company rating was upgraded by BTIG Research.

The stock increased 0.51% or $0.3 on September 15, reaching $59.46. About 565,554 shares traded or 63.14% up from the average. Insulet Corporation (NDAQ:PODD) has risen 48.83% since September 17, 2016 and is uptrending. It has outperformed by 32.13% the S&P500.

Wall Street await Insulet Corporation (NASDAQ:PODD) to release earnings on November, 2. Analysts forecast EPS of $-0.11, down exactly $0.06 or 120.00 % from 2014’s $-0.05 EPS. After posting $-0.13 EPS for the previous quarter, Insulet Corporation’s analysts now forecast -15.38 % EPS growth.

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System , an insulin delivery system for people with insulin-dependent diabetes. The company has market cap of $3.45 billion. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). It currently has negative earnings. The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter.

More recent Insulet Corporation (NASDAQ:PODD) news were published by: Globenewswire.com which released: “United States $3.8 Billion Insulin Pump Market 2017-2022 with Insulet …” on August 25, 2017. Also Businesswire.com published the news titled: “Insulin Management System in Approximately 39000 Patients Using a Cloud-Based …” on September 13, 2017. Globenewswire.com‘s news article titled: “USA Insulin Pump Market, 2022: Leading Companies are Medtronic, Insulet …” with publication date: August 22, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: